Silver Book Fact

Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.

Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield. Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform. Diabetes Care. 1994; 17(8): 909-17. http://care.diabetesjournals.org/cgi/content/abstract/17/8/909

Reference

Title
Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform
Publication
Diabetes Care
Publication Date
1994
Authors
Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield
Volume & Issue
Volume 17, Issue 8
Pages
909-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%